🇺🇸 FDA

Intelligence · Clinical Pipeline

Phase II Pipeline Programs

Proof-of-concept and dose-finding clinical programs in Phase II development.

Programs
7,238

Quick answer

NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.

Top sponsors

Page 72 of 151

  1. LAAM

    BRIGHT MINDS BIOSCIENCES INC.

    Behavior Therapy

    phase 2 other completed

    1 trial

  2. LAB4

    Cardiff Oncology

    Graves' Disease

    phase 2 mab active

    1 trial

  3. LAD328, SODIUM CHLORIDE

    Almirall, S.A.

    moderate-to-severe hidradenitis suppurativa

    phase 2 small molecule active

    1 trial

  4. LB-100

    LIXTE BIOTECHNOLOGY HOLDINGS, INC.

    Myelodysplastic Syndromes

    phase 2 small molecule active

    1 trial

  5. LB-102

    LB PHARMACEUTICALS INC

    Bipolar I Disorder

    phase 2 small molecule active

    1 trial

  6. LB-208, LB-208

    AOP Orphan Pharmaceuticals GmbH

    Relapse or refractory (r/r) acute myeloid leukaemia (AML) and r/r higher-risk (HR) myelodysplastic syndrome (MDS)

    phase 2 small molecule active

    1 trial

  7. LB101

    Centessa Pharmaceuticals plc

    Advanced Solid Tumor

    phase 2 small molecule terminated

    1 trial

  8. LB1410

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Solid Tumor

    phase 2 small molecule active

    1 trial

  9. LB54640

    Rhythm Pharmaceuticals Netherlands B.V.

    Hypothalamic Obesity

    phase 2 small molecule completed

    1 trial

  10. LBH581

    BRIGHT MINDS BIOSCIENCES INC.

    Small Cell Lung Carcinoma

    phase 2 small molecule completed

    1 trial

  11. LBL-007

    BEONE MEDICINES AUS PTY LTD

    Esophageal Cancer

    phase 2 small molecule active

    1 trial

  12. LBL-024 for Injection

    The First People's Hospital of Lianyungang

    Triple Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  13. LBR-101 High Dose

    Teva Pharma GmbH

    Episodic Migraine Headache

    phase 2 small molecule completed

    1 trial

  14. LBR-101 High Dose

    Teva Pharma GmbH

    Chronic Migraine

    phase 2 small molecule completed

    1 trial

  15. LCAR-B38M CAR-T Cell

    Nanjing Legend Biotech Co.

    Multiple Myeloma

    phase 2 mab terminated

    1 trial

  16. LCAR-B38M CAR-T cell injection

    Nanjing Legend Biotech Co.

    Refractory or Relapsed Multiple Myeloma

    phase 2 mab active

    1 trial

  17. LCZ696

    Novartis Pharmaceuticals

    Hypertension

    phase 2 small molecule completed

    2 trials

  18. LDE225 0.75%

    Novartis Pharmaceuticals

    Sporadic Superficial and Nodular Skin Basal Cell Carcinomas

    phase 2 small molecule terminated

    1 trial

  19. LEAn Body Mass Normalization of OXaliplatin Based Chemotherapy

    The George Institute

    Colon cancer

    phase 2 other active

    1 trial

  20. LEE011, LEE011, LTT462, LXH254, LXH254, TMT212, LXH254, LTT462, LXH254

    Novartis Pharmaceuticals

    Previously treated unresectable or metastatic BRAFV600 or NRAS mutant melanoma

    phase 2 small molecule active

    1 trial

  21. LEE011, TMT212, Mekinist 2 mg film-coated tablets, Mekinist 0.5 mg film-coated tablets, TMT212, JDQ443, CETUXIMAB

    Novartis Pharmaceuticals

    Adult patients with advanced (metastatic or unresectable) KRAS G12C mutant solid tumors

    phase 2 small molecule active

    1 trial

  22. LEN+SIN+DEB-TACE+HAIC

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hepatocellular Carcinoma Non-resectable

    phase 2 other active

    1 trial

  23. LENALIDOMIDE, LENALIDOMIDE, DEXAMETHASONE, CARFILZOMIB, LENALIDOMIDE, DARATUMUMAB, LENALIDOMIDE, Etentamig, LENALIDOMIDE, LENALIDOMIDE, DEXAMETHASONE

    AbbVie Deutschland GmbH & Co. KG

    Multiple Myeloma

    phase 2 small molecule active

    1 trial

  24. LENALIDOMIDE, LENALIDOMIDE, DEXAMETHASONE, LENALIDOMIDE, DEXAMETHASONE, LENALIDOMIDE, LENALIDOMIDE

    Wuhan Createrna Science and Technology Co., Ltd

    Newly diagnosed patients with multiple myeloma

    phase 2 small molecule active

    1 trial

  25. LENALIDOMIDE, PYRIMETHAMINE, TOPIRAMATE

    Disc Medicine

    HIV-1

    phase 2 small molecule active

    1 trial

  26. LENOGRASTIM , RITUXIMAB, BUSULFAN , FLUDARABINE , PLERIXAFOR , OTL-203

    Orchard Therapeutics (Netherlands) B.V.

    Mucopolysaccharidosis type I Hurler

    phase 2 small molecule active

    1 trial

  27. LENVATINIB, KEYTRUDA 25 mg/mL concentrate for solution for infusion.

    Disc Medicine

    high risk or poor response after chemoradiation and brachytherapy for locally advanced cervix cancer

    phase 2 small molecule active

    1 trial

  28. LENVIMA 4 mg hard capsules

    Pari Pharma GmbH

    Non-resectable hepatocellular carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  29. LENVIMA 4 mg hard capsules

    Pari Pharma GmbH

    Patients with Biopsy-proven or radiologically-suggested BCLC A HCC eligible for PA and comprising at least one of the following criteria: - Single tumour>3 cm≤ 5cm or - multiple tumours (max 3 lesions ≤ 3cm) or - Single tumour between 2 and 3 cm with at least one of the following characteristic: • Serum AFP>100 ng/mL • Infiltrative form • Macro-trabecular subtype (if applicable)

    phase 2 small molecule active

    1 trial

  30. LENVIMA 4 mg hard capsules, E7386, KEYTRUDA 25 mg/mL concentrate for solution for infusion, E7386, LENVIMA 10 mg hard capsules

    Eisai Co.,

    colorectal cancer, melanoma, hepatocellular carcinoma

    phase 2 small molecule active

    1 trial

  31. LENVIMA 4 mg hard capsules, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    The George Institute

    advanced stage hepatocellular carcinoma

    phase 2 small molecule active

    1 trial

  32. LEO 90105

    LEO Pharma A/S

    Psoriasis Vulgaris

    phase 2 small molecule completed

    1 trial

  33. LETROZOLE ACCORD HEALTHCARE 2,5 mg, comprimé pelliculé, Kisqali 200 mg film-coated tablets, RIBOCICLIB, INAVOLISIB, RIBOCICLIB, LETROZOLE, INAVOLISIB, LETROZOLE, Letrozol STADA® 2,5 mg Filmtabletten

    Hoffmann-La Roche

    Early-Stage, PIK3CA-Mutated Breast Cancer (BC)

    phase 2 small molecule active

    1 trial

  34. LETROZOLE, FULVESTRANT

    Pfizer Australia Pty Ltd

    Part 2A, 2B, 2C & 2E HR-positive /HER2-negative breast cancer, Part 1F Prostate cancer, Part 2D mCRPC, Part 1A/Part 1D/Part1E Breast cancer, NSCLC, prostate, CRC, liposarcoma, or tumors with previously confirmed CDK4 or CCND1 amplification., Part 1B &1C HR-positive/HER2-negative breast cancer

    phase 2 small molecule active

    1 trial

  35. LEUPRORELIN ACETATE, FULVESTRANT, ECI830, GOSERELIN, LEUPRORELIN ACETATE, GOSERELIN, RIBOCICLIB, ECI830, ECI830

    Novartis Pharmaceuticals

    Advanced solid tumors, Advanced HR+/HER2- breast cancer

    phase 2 small molecule active

    1 trial

  36. LEUPRORELIN ACETATE, LETROZOLE, GVV858, LEUPRORELIN ACETATE, FULVESTRANT, GVV858, GOSERELIN, GOSERELIN

    Novartis Pharmaceuticals

    Advanced HR+/HER- breast cancer

    phase 2 small molecule active

    1 trial

  37. LEVOFOLINATE DE CALCIUM ZENTIVA 10 mg/ml, solution injectable (IM/IV), Docetaxel Accord 20 mg/1 ml concentrate for solution for infusion, Bemarituzumab, FLUOROURACILE ACCORD 50 mg/ml, solution à diluer pour perfusion, OXALIPLATINE ACCORD 5 mg/ml, solution à diluer pour perfusion

    CERO THERAPEUTICS HOLDINGS, INC.

    gastric and gastro-oesophageal junction adenocarcinomas

    phase 2 small molecule active

    1 trial

  38. LGD-6972-5 mg

    LIGAND PHARMACEUTICALS INC

    Type 2 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  39. LIBTAYO 350 mg concentrate for solution for infusion.

    The George Institute

    Cutaneous squamous cell carcinoma (ccSCC)

    phase 2 small molecule active

    1 trial

  40. LIBTAYO 350 mg concentrate for solution for infusion.

    The George Institute

    basal cell carcinoma

    phase 2 small molecule active

    1 trial

  41. LIBTAYO 350 mg concentrate for solution for infusion., Fianlimab

    Lacuna Pharma Pty Ltd

    Melanoma

    phase 2 small molecule active

    1 trial

  42. LIBTAYO 350 mg concentrate for solution for infusion., IMUNOCARE 5% crema

    The George Institute

    Cutaneous Basal Cell Carcinoma

    phase 2 small molecule active

    1 trial

  43. LIBTAYO 350 mg concentrate for solution for infusion., LIBTAYO 350 mg concentrate for solution for infusion., LIBTAYO 350 mg concentrate for solution for infusion., LIBTAYO 350 mg concentrate for solution for infusion., REGN10597

    Lacuna Pharma Pty Ltd

    Melanoma, Advanced Solid Tumours, Clear-Cell Renal-Cell Carcinoma (ccRCC)

    phase 2 small molecule active

    1 trial

  44. LIBTAYO 350 mg concentrate for solution for infusion., M1774, M1774, M1774

    Merck Sharp and Dohme

    Non-Squamous Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  45. LIBTAYO 350 mg concentrate for solution for infusion., THIO

    MAIA Biotechnology

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  46. LIBTAYO 350 mg concentrate for solution for infusion., Vidutolimod, Vidutolimod

    Lacuna Pharma Pty Ltd

    Advanced or Metastatic Cancer Merkel Cell Carcinoma (MCC) Cutaneous Squamous Cell Carcinoma (CSCC) Basal Cell Carcinoma (BCC) Triple Negative Breast Cancer (TNBC) Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  47. LICSBR

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Locally Advanced Pancreatic Ductal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  48. LIK066

    Novartis Pharmaceuticals

    Obese Patients With Non-alcoholic Steatohepatitis (NASH)

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many Phase II pipeline programs are in the directory?

7,238 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.